Ipamorelin is a selective gh-secretagogue increasingly recognized for its ability to facilitate effortless recovery through natural growth hormone (GH) stimulation. Research professionals and wellness enthusiasts alike are exploring peptides like ipamorelin for their precise mechanisms and low risk of adverse effects, distinguishing them from older GH-boosting agents. At Oath Research, our commitment is to providing high-quality research materials, and understanding compounds like ipamorelin is crucial for advancement in the peptide field.
Updated on March 4, 2026 — references verified, newer research added.
What is a GH-Secretagogue — and What Makes Ipamorelin Selective?
A gh-secretagogue is a compound that stimulates the secretion of growth hormone, promoting tissue regeneration, metabolic optimization, and recovery. Ipamorelin stands out among gh-secretagogue peptides due to its selective nature. It primarily targets the ghrelin receptor (also known as the growth hormone secretagogue receptor, GHS-R1a) within the pituitary gland and hypothalamus. The result? A potent, controlled increase in GH-pulse activity—delivering the benefits of raised growth hormone levels without overstimulation or dangerous spikes in cortisol or prolactin [1][2].
Classic gh-secretagogues such as GHRP-2 and GHRP-6 often increase the release of additional hormones (like cortisol or acetylcholine), which can lead to unwanted “sides,” or side effects. Ipamorelin’s refined, selective interaction with the ghrelin receptor is why it’s often associated with “low-sides,” making it an attractive option for researchers dedicated to exploring tissue regeneration, anti-aging, and recovery without unnecessary complications. A 2020 review in Translational Andrology and Urology confirms ipamorelin’s selectivity for GHSR-1a and its favorable side-effect profile compared to other GH secretagogues [6].
Understanding the Role of Ghrelin and GH-Pulse Modulation
Ghrelin is a peptide hormone that plays a major role in appetite signaling and the regulation of growth hormone release. Ipamorelin’s unique molecular design allows it to mimic certain aspects of ghrelin by binding selectively to its receptor, thereby stimulating a natural and robust GH-pulse. This rhythm of growth hormone secretion is essential for downstream effects such as increased muscle protein synthesis, enhanced fat metabolism, improved sleep quality, and—most importantly for research—accelerated tissue recovery.
By enhancing the amplitude and frequency of GH-pulse events without overstimulation, ipamorelin can more closely emulate a youthful growth hormone profile. This property is highly valuable for exploring age-related recovery decline and developing interventions in laboratory or clinical research models. For reference, further details on the biological interactions of ghrelin and secretagogue pathways can be found in the foundational review by Kojima & Kangawa (2005) [3]. More recently, cryo-EM structural studies (2021–2022) have elucidated the molecular basis of GHS-R1a activation at the atomic level, and biased receptor signaling at GHSR-1a has emerged as an active research area with therapeutic relevance [5].
Ipamorelin as a Low-Sides Peptide for Recovery Research
One of the key reasons for ipamorelin’s surge in popularity as a selective gh-secretagogue in the scientific community is its favorable side-effect profile. Most classic secretagogues can trigger broad hormonal cascades, often resulting in side effects like water retention, appetite swings, or elevated cortisol/prolactin. Ipamorelin’s low-sides nature is due to its selective action—the landmark Raun et al. (1998) study established that ipamorelin has minimal impact on aldosterone, prolactin, or acetylcholine levels, distinguishing it from GHRP-2 and GHRP-6 [1].
Researchers aiming to investigate mechanisms of muscle repair, post-exercise recovery, or metabolic wellness often rely on peptides with clean profiles. Peptides like ipamorelin provide a controlled experimental environment without the confounding variables of systemic hormone imbalances. For those pursuing synergistic recovery pathways, blends like the CJC-1295/Ipamorelin combination (available at OathPeptides.com) offer a dual-action approach for more comprehensive GH-pulse research.
Comparing Ipamorelin to Other Recovery-Enhancing Peptides
The peptide research landscape is rich with gh-secretagogue options, but not all are created equal. Let’s briefly compare some popular research peptides for recovery:
– GHRP-2 and GHRP-6: Potent, but often associated with increased cortisol and prolactin.
– Sermorelin: Mimics native GHRH, but may require more frequent dosing.
– CJC-1295: Offers prolonged GH release, often paired with selective secretagogues for optimal effect.
– BPC-157 and TB-500: Focused more on connective tissue healing and angiogenesis, rather than GH release—but often stacked alongside ipamorelin for multifaceted recovery.
– CJC-1295/Ipamorelin Blend: Combines the strengths of both molecules for a high-impact, low-sides recovery solution (more on this CJC-1295/Ipamorelin blend at OathPeptides.com).
Each of these compounds has a slightly different research focus. Still, ipamorelin remains a strong candidate whenever selective, controlled GH-pulse stimulation and low risk of side effects is central to your model. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research Review specifically identifies ipamorelin as a growth hormone secretagogue that activates IGF-1 signaling and satellite cell repair pathways, while noting that broader human clinical trials are still needed [8].
Optimizing GH-Pulse for Faster Recovery
Prolonged stresses, intense exercise, illness, or aging can blunt regular GH-pulse patterns, slowing the healing process. Ipamorelin’s ability to modulate the natural ebb and flow of growth hormone pulses means recovery can be enhanced—whether in muscle tissue, connective tissue, or even neurological contexts.
Researchers have observed improvements in cellular repair rates, collagen synthesis, wound healing, and lipid breakdown correlated with the steady, reproducible GH-pulses seen with ipamorelin administration (preclinical models) [2]. This suggests its broad appeal in labs focusing on sports recovery, metabolic decline, or regenerative medicine. A 2024 study published in Physiology & Behavior further demonstrated that ipamorelin, acting as a GHS-R1a agonist, inhibited cisplatin-induced weight loss by approximately 24% during the delayed phase in ferret models—highlighting its anti-catabolic and metabolic protective properties beyond simple GH-pulse enhancement [7].
Synergistic Research: Combining Ipamorelin and Other Peptides
One avenue gaining momentum is peptide synergy. For example, stacking ipamorelin with CJC-1295 enhances the overall duration and amplitude of GH-pulses while retaining a low-sides profile. Some labs pair ipamorelin with BPC-157 or TB-500 to accelerate soft tissue recovery, particularly after injury or surgery. These multi-peptide regimens allow for multi-axis recovery protocols that reduce the confounding effects of single-hormone overexpression.
A 2026 review published in the American Journal of Sports Medicine (Mayfield et al.) reported that CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models experiencing glucocorticoid-induced muscle loss [9]. The authors emphasize that current evidence is limited to animal studies and that significant further research is required before clinical recommendations can be made—reinforcing the importance of ongoing preclinical research with compounds like ipamorelin.
Related product: Read more about the popular CJC-1295/Ipamorelin blend and its applications for research studies on effortless recovery.
Safety Profile: Sustainable Research with Low Sides
A persistent concern with any gh-secretagogue is managing unwanted “sides.” Ipamorelin’s ability to induce consistent, controlled GH increases without elevating cortisol or prolactin places it in a unique safety bracket. The only published human randomized controlled trial of ipamorelin—Beck et al. (2014)—found that ipamorelin was well tolerated in postoperative patients, with good safety and tolerability data, while producing no significant efficacy difference vs. placebo for postoperative ileus [4]. The pharmacokinetic study by Gobburu et al. (1999) similarly documents safe human administration with consistent GH-pulse responses [2].
As always, it’s essential to note: All products provided by OathPeptides.com are strictly for research purposes and not for human or animal use. Responsible handling, ethical design, and adherence to local protocols are mandatory.
Note on Regulatory Landscape (2024): Researchers tracking the regulatory environment should be aware that in September 2024, the FDA removed ipamorelin acetate from Category 2 of the 503A interim bulks list, with ongoing review by the Pharmacy Compounding Advisory Committee (PCAC). This regulatory development underscores the evolving status of ipamorelin and the importance of maintaining current research-only framing for all laboratory applications.
Frequently Asked Questions (FAQ)
Q1: What exactly makes ipamorelin a selective gh-secretagogue?
Ipamorelin’s selectivity comes from targeting the ghrelin receptor in a highly specific manner. Unlike some peptides, it does not broadly activate other hormone pathways, resulting in fewer “sides” and greater experimental control. This was first established in the foundational Raun et al. (1998) study [1].
Q2: How does GH-pulse modulation affect recovery in research?
By increasing the frequency and amplitude of growth hormone pulses, ipamorelin supports more rapid cellular repair, protein synthesis, and metabolic recovery—ideal for studies on injury, aging, or athletic stress.
Q3: Can ipamorelin be combined with other peptides for research?
Absolutely. It’s often paired with CJC-1295 for a powerful GH-pulse synergy or with peptides like BPC-157 to enhance tissue-specific recovery. Learn more about these multi-peptide blends at OathPeptides.com.
Q4: What are “low-sides” and why does ipamorelin matter for this?
“Low-sides” refers to a minimized risk of adverse effects from off-target hormone release (like cortisol or prolactin). Ipamorelin is specifically valued for this feature in research environments.
Q5: Is ipamorelin suitable for all types of recovery protocols?
While ipamorelin supports generalized recovery through GH-pulse optimization, specific protocol suitability depends on study design, target tissue, and compliance with regulatory guidelines.
Q6: What does emerging pain research show about ipamorelin?
A 2020 peer-reviewed study (Mohammadi et al., Journal of Experimental Pharmacology) demonstrated that ipamorelin significantly attenuated both visceral and somatic nociception in animal models via GHS-R1a mechanisms [10]. Effects were dose-dependent and reversible with a GHS-R antagonist, identifying GHS-R1a-mediated anti-nociception as a novel and unexplored research avenue for ipamorelin. All applications remain strictly for research use only.
Conclusion: Ipamorelin’s Place in Effortless Recovery Research
As a selective gh-secretagogue, ipamorelin offers the rare combination of potent GH-pulse stimulation, low sides, and precise recovery modulation. For scientists looking to advance recovery research—whether it’s muscle repair after intense exertion, neurological resilience, or metabolic rebound—ipamorelin provides a safe and versatile tool. Ongoing 2024–2026 research continues to expand the scope of ipamorelin’s recognized applications, from musculoskeletal repair to anti-catabolic protection and pain research.
Explore our full collection of research-grade peptides (from dedicated ipamorelin formulations to dynamic blends like CJC-1295/Ipamorelin) at OathPeptides.com. Each product is prepared for research purposes only—supporting your lab’s vision for discovery, innovation, and effortless recovery.
References
1. Raun, K., et al. (1998). “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. https://pubmed.ncbi.nlm.nih.gov/9849822/
2. Gobburu, J.V.S., et al. (1999). “Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.” Pharmaceutical Research. https://pubmed.ncbi.nlm.nih.gov/10496658/
3. Kojima, M., & Kangawa, K. (2005). “Ghrelin: structure and function.” Physiological Reviews. https://pubmed.ncbi.nlm.nih.gov/15788704/
4. Beck, D.E., et al. (2014). “Ipamorelin for postoperative ileus: a multicenter, randomized, placebo-controlled trial.” Diseases of the Colon & Rectum. https://pubmed.ncbi.nlm.nih.gov/25331030/
5. Gross, L.Z.F., et al. (2023). “Biased signaling at the growth hormone secretagogue receptor.” Trends in Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/36567228/
6. Sigalos, J.T., & Zito, P.M. (2020). “Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.” Translational Andrology and Urology. https://pubmed.ncbi.nlm.nih.gov/32257855/
7. Lu, Z., et al. (2024). “The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets.” Physiology & Behavior. https://pubmed.ncbi.nlm.nih.gov/39043357/
8. Bhatt, V., et al. (2026). “Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.” Journal of the American Academy of Orthopaedic Surgeons Global Research Review. https://pubmed.ncbi.nlm.nih.gov/41490200/
9. Mayfield, C.K., et al. (2026). “Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.” American Journal of Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41476424/
10. Mohammadi, M., et al. (2020). “Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.” Journal of Experimental Pharmacology. https://pubmed.ncbi.nlm.nih.gov/32801950/
For related research peptides supporting recovery, discover our BPC-157/TB-500 blend and CJC-1295/Ipamorelin peptide, both designed for advanced laboratory exploration.
The legal status of Ipamorelin has shifted dramatically in recent years. As of 2024, the FDA prohibited compounding pharmacies from producing Ipamorelin following its inclusion on the Agency’s “Difficult to Compound” list. This regulatory change surprised many researchers and clinicians who had relied on compounded peptide formulations for experimental protocols. Understanding where Ipamorelin stands legally …
Ipamorelin Peptide: Selective GH-Secretagogue for Effortless Recovery
Ipamorelin is a selective gh-secretagogue increasingly recognized for its ability to facilitate effortless recovery through natural growth hormone (GH) stimulation. Research professionals and wellness enthusiasts alike are exploring peptides like ipamorelin for their precise mechanisms and low risk of adverse effects, distinguishing them from older GH-boosting agents. At Oath Research, our commitment is to providing high-quality research materials, and understanding compounds like ipamorelin is crucial for advancement in the peptide field.
Updated on March 4, 2026 — references verified, newer research added.
What is a GH-Secretagogue — and What Makes Ipamorelin Selective?
A gh-secretagogue is a compound that stimulates the secretion of growth hormone, promoting tissue regeneration, metabolic optimization, and recovery. Ipamorelin stands out among gh-secretagogue peptides due to its selective nature. It primarily targets the ghrelin receptor (also known as the growth hormone secretagogue receptor, GHS-R1a) within the pituitary gland and hypothalamus. The result? A potent, controlled increase in GH-pulse activity—delivering the benefits of raised growth hormone levels without overstimulation or dangerous spikes in cortisol or prolactin [1][2].
Classic gh-secretagogues such as GHRP-2 and GHRP-6 often increase the release of additional hormones (like cortisol or acetylcholine), which can lead to unwanted “sides,” or side effects. Ipamorelin’s refined, selective interaction with the ghrelin receptor is why it’s often associated with “low-sides,” making it an attractive option for researchers dedicated to exploring tissue regeneration, anti-aging, and recovery without unnecessary complications. A 2020 review in Translational Andrology and Urology confirms ipamorelin’s selectivity for GHSR-1a and its favorable side-effect profile compared to other GH secretagogues [6].
Understanding the Role of Ghrelin and GH-Pulse Modulation
Ghrelin is a peptide hormone that plays a major role in appetite signaling and the regulation of growth hormone release. Ipamorelin’s unique molecular design allows it to mimic certain aspects of ghrelin by binding selectively to its receptor, thereby stimulating a natural and robust GH-pulse. This rhythm of growth hormone secretion is essential for downstream effects such as increased muscle protein synthesis, enhanced fat metabolism, improved sleep quality, and—most importantly for research—accelerated tissue recovery.
By enhancing the amplitude and frequency of GH-pulse events without overstimulation, ipamorelin can more closely emulate a youthful growth hormone profile. This property is highly valuable for exploring age-related recovery decline and developing interventions in laboratory or clinical research models. For reference, further details on the biological interactions of ghrelin and secretagogue pathways can be found in the foundational review by Kojima & Kangawa (2005) [3]. More recently, cryo-EM structural studies (2021–2022) have elucidated the molecular basis of GHS-R1a activation at the atomic level, and biased receptor signaling at GHSR-1a has emerged as an active research area with therapeutic relevance [5].
Ipamorelin as a Low-Sides Peptide for Recovery Research
One of the key reasons for ipamorelin’s surge in popularity as a selective gh-secretagogue in the scientific community is its favorable side-effect profile. Most classic secretagogues can trigger broad hormonal cascades, often resulting in side effects like water retention, appetite swings, or elevated cortisol/prolactin. Ipamorelin’s low-sides nature is due to its selective action—the landmark Raun et al. (1998) study established that ipamorelin has minimal impact on aldosterone, prolactin, or acetylcholine levels, distinguishing it from GHRP-2 and GHRP-6 [1].
Researchers aiming to investigate mechanisms of muscle repair, post-exercise recovery, or metabolic wellness often rely on peptides with clean profiles. Peptides like ipamorelin provide a controlled experimental environment without the confounding variables of systemic hormone imbalances. For those pursuing synergistic recovery pathways, blends like the CJC-1295/Ipamorelin combination (available at OathPeptides.com) offer a dual-action approach for more comprehensive GH-pulse research.
Comparing Ipamorelin to Other Recovery-Enhancing Peptides
The peptide research landscape is rich with gh-secretagogue options, but not all are created equal. Let’s briefly compare some popular research peptides for recovery:
– GHRP-2 and GHRP-6: Potent, but often associated with increased cortisol and prolactin.
– Sermorelin: Mimics native GHRH, but may require more frequent dosing.
– CJC-1295: Offers prolonged GH release, often paired with selective secretagogues for optimal effect.
– BPC-157 and TB-500: Focused more on connective tissue healing and angiogenesis, rather than GH release—but often stacked alongside ipamorelin for multifaceted recovery.
– CJC-1295/Ipamorelin Blend: Combines the strengths of both molecules for a high-impact, low-sides recovery solution (more on this CJC-1295/Ipamorelin blend at OathPeptides.com).
Each of these compounds has a slightly different research focus. Still, ipamorelin remains a strong candidate whenever selective, controlled GH-pulse stimulation and low risk of side effects is central to your model. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research Review specifically identifies ipamorelin as a growth hormone secretagogue that activates IGF-1 signaling and satellite cell repair pathways, while noting that broader human clinical trials are still needed [8].
Optimizing GH-Pulse for Faster Recovery
Prolonged stresses, intense exercise, illness, or aging can blunt regular GH-pulse patterns, slowing the healing process. Ipamorelin’s ability to modulate the natural ebb and flow of growth hormone pulses means recovery can be enhanced—whether in muscle tissue, connective tissue, or even neurological contexts.
Researchers have observed improvements in cellular repair rates, collagen synthesis, wound healing, and lipid breakdown correlated with the steady, reproducible GH-pulses seen with ipamorelin administration (preclinical models) [2]. This suggests its broad appeal in labs focusing on sports recovery, metabolic decline, or regenerative medicine. A 2024 study published in Physiology & Behavior further demonstrated that ipamorelin, acting as a GHS-R1a agonist, inhibited cisplatin-induced weight loss by approximately 24% during the delayed phase in ferret models—highlighting its anti-catabolic and metabolic protective properties beyond simple GH-pulse enhancement [7].
Synergistic Research: Combining Ipamorelin and Other Peptides
One avenue gaining momentum is peptide synergy. For example, stacking ipamorelin with CJC-1295 enhances the overall duration and amplitude of GH-pulses while retaining a low-sides profile. Some labs pair ipamorelin with BPC-157 or TB-500 to accelerate soft tissue recovery, particularly after injury or surgery. These multi-peptide regimens allow for multi-axis recovery protocols that reduce the confounding effects of single-hormone overexpression.
A 2026 review published in the American Journal of Sports Medicine (Mayfield et al.) reported that CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models experiencing glucocorticoid-induced muscle loss [9]. The authors emphasize that current evidence is limited to animal studies and that significant further research is required before clinical recommendations can be made—reinforcing the importance of ongoing preclinical research with compounds like ipamorelin.
Related product: Read more about the popular CJC-1295/Ipamorelin blend and its applications for research studies on effortless recovery.
Safety Profile: Sustainable Research with Low Sides
A persistent concern with any gh-secretagogue is managing unwanted “sides.” Ipamorelin’s ability to induce consistent, controlled GH increases without elevating cortisol or prolactin places it in a unique safety bracket. The only published human randomized controlled trial of ipamorelin—Beck et al. (2014)—found that ipamorelin was well tolerated in postoperative patients, with good safety and tolerability data, while producing no significant efficacy difference vs. placebo for postoperative ileus [4]. The pharmacokinetic study by Gobburu et al. (1999) similarly documents safe human administration with consistent GH-pulse responses [2].
As always, it’s essential to note: All products provided by OathPeptides.com are strictly for research purposes and not for human or animal use. Responsible handling, ethical design, and adherence to local protocols are mandatory.
Note on Regulatory Landscape (2024): Researchers tracking the regulatory environment should be aware that in September 2024, the FDA removed ipamorelin acetate from Category 2 of the 503A interim bulks list, with ongoing review by the Pharmacy Compounding Advisory Committee (PCAC). This regulatory development underscores the evolving status of ipamorelin and the importance of maintaining current research-only framing for all laboratory applications.
Frequently Asked Questions (FAQ)
Q1: What exactly makes ipamorelin a selective gh-secretagogue?
Ipamorelin’s selectivity comes from targeting the ghrelin receptor in a highly specific manner. Unlike some peptides, it does not broadly activate other hormone pathways, resulting in fewer “sides” and greater experimental control. This was first established in the foundational Raun et al. (1998) study [1].
Q2: How does GH-pulse modulation affect recovery in research?
By increasing the frequency and amplitude of growth hormone pulses, ipamorelin supports more rapid cellular repair, protein synthesis, and metabolic recovery—ideal for studies on injury, aging, or athletic stress.
Q3: Can ipamorelin be combined with other peptides for research?
Absolutely. It’s often paired with CJC-1295 for a powerful GH-pulse synergy or with peptides like BPC-157 to enhance tissue-specific recovery. Learn more about these multi-peptide blends at OathPeptides.com.
Q4: What are “low-sides” and why does ipamorelin matter for this?
“Low-sides” refers to a minimized risk of adverse effects from off-target hormone release (like cortisol or prolactin). Ipamorelin is specifically valued for this feature in research environments.
Q5: Is ipamorelin suitable for all types of recovery protocols?
While ipamorelin supports generalized recovery through GH-pulse optimization, specific protocol suitability depends on study design, target tissue, and compliance with regulatory guidelines.
Q6: What does emerging pain research show about ipamorelin?
A 2020 peer-reviewed study (Mohammadi et al., Journal of Experimental Pharmacology) demonstrated that ipamorelin significantly attenuated both visceral and somatic nociception in animal models via GHS-R1a mechanisms [10]. Effects were dose-dependent and reversible with a GHS-R antagonist, identifying GHS-R1a-mediated anti-nociception as a novel and unexplored research avenue for ipamorelin. All applications remain strictly for research use only.
Conclusion: Ipamorelin’s Place in Effortless Recovery Research
As a selective gh-secretagogue, ipamorelin offers the rare combination of potent GH-pulse stimulation, low sides, and precise recovery modulation. For scientists looking to advance recovery research—whether it’s muscle repair after intense exertion, neurological resilience, or metabolic rebound—ipamorelin provides a safe and versatile tool. Ongoing 2024–2026 research continues to expand the scope of ipamorelin’s recognized applications, from musculoskeletal repair to anti-catabolic protection and pain research.
Explore our full collection of research-grade peptides (from dedicated ipamorelin formulations to dynamic blends like CJC-1295/Ipamorelin) at OathPeptides.com. Each product is prepared for research purposes only—supporting your lab’s vision for discovery, innovation, and effortless recovery.
References
1. Raun, K., et al. (1998). “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. https://pubmed.ncbi.nlm.nih.gov/9849822/
2. Gobburu, J.V.S., et al. (1999). “Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.” Pharmaceutical Research. https://pubmed.ncbi.nlm.nih.gov/10496658/
3. Kojima, M., & Kangawa, K. (2005). “Ghrelin: structure and function.” Physiological Reviews. https://pubmed.ncbi.nlm.nih.gov/15788704/
4. Beck, D.E., et al. (2014). “Ipamorelin for postoperative ileus: a multicenter, randomized, placebo-controlled trial.” Diseases of the Colon & Rectum. https://pubmed.ncbi.nlm.nih.gov/25331030/
5. Gross, L.Z.F., et al. (2023). “Biased signaling at the growth hormone secretagogue receptor.” Trends in Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/36567228/
6. Sigalos, J.T., & Zito, P.M. (2020). “Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.” Translational Andrology and Urology. https://pubmed.ncbi.nlm.nih.gov/32257855/
7. Lu, Z., et al. (2024). “The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets.” Physiology & Behavior. https://pubmed.ncbi.nlm.nih.gov/39043357/
8. Bhatt, V., et al. (2026). “Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.” Journal of the American Academy of Orthopaedic Surgeons Global Research Review. https://pubmed.ncbi.nlm.nih.gov/41490200/
9. Mayfield, C.K., et al. (2026). “Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.” American Journal of Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41476424/
10. Mohammadi, M., et al. (2020). “Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.” Journal of Experimental Pharmacology. https://pubmed.ncbi.nlm.nih.gov/32801950/
For related research peptides supporting recovery, discover our BPC-157/TB-500 blend and CJC-1295/Ipamorelin peptide, both designed for advanced laboratory exploration.
Related Posts
Is Ipamorelin Still Legal to Use?
The legal status of Ipamorelin has shifted dramatically in recent years. As of 2024, the FDA prohibited compounding pharmacies from producing Ipamorelin following its inclusion on the Agency’s “Difficult to Compound” list. This regulatory change surprised many researchers and clinicians who had relied on compounded peptide formulations for experimental protocols. Understanding where Ipamorelin stands legally …